Compare · head to head
Caribou Biosciences vs Incyte
Incyte ranks higher overall — 360 rank 95 vs 39.
Incyte leads on Value (70 vs 35), Quality (68 vs 44) and Safety (68 vs 49). Caribou Biosciences leads on Growth (65 vs 56). The two are close on Sentiment.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Small | Large |
| ISIN | US1420381089 | US45337C1027 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 39 | 95 |
| Value | 35 | 70 |
| Quality | 44 | 68 |
| Growth | 65 | 56 |
| Safety | 49 | 68 |
| Sentiment | 46 | 44 |
| Quality details | ||
| Profitability | 30 | 84 |
| Cash Truth | 57 | 51 |
Caribou Biosciences vs Adaptive BiotechnologiesCaribou Biosciences vs Legend BiotechCaribou Biosciences vs Zenas BiopharmaAdd a third stock →
Full analyses: Caribou Biosciences · Incyte
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100